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ABSTRACT
The human CD44 gene encodes multiple isoforms of a transmembrane protein that differ in their extracellular domains as a
result of alternative splicing of its variable exons. Expression of CD44 is tightly regulated according to the type and physiological
status of a cell, with expression of high molecular weight isoforms by inclusion of variable exons and low molecular weight
isoforms containing few or no variable exons. Human CD44 variable exon 3 (v3) can follow a specific alternative splicing route
different from that affecting other variable exons. Here we map and functionally describe the splicing enhancer element within
CD44 exon v3 which regulates its inclusion in the final mRNA. The v3 splicing enhancer is a multisite bipartite element
consisting of a tandem nonamer, the XX motif, and an heptamer, the Y motif, located centrally in the exon. Each of the three
sites of this multisite enhancer partially retains its splicing enhancing capacity independently from each other in CD44 and
shows full enhancing function in gene contexts different from CD44. We further demonstrate that these motifs act cooperatively
as at least two motifs are needed to maintain exon inclusion. Their action is differential with respect to the splice-site target
abutting v3. The first X motif acts on the 39 splice site, the second X motif acts on both splice sites (as a bidirectional exonic
splicing enhancer), and the Y motif acts on the 59 splice site. We also show that the multisite v3 splicing enhancer is functional
irrespective of flanking intron length and spatial organization within v3.
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INTRODUCTION
Alternative pre-mRNA splicing is a very common event in
higher eukaryotes which enables the production of multiple
mRNA isoforms from a single gene. Alternative splicing pro-
vides a powerful means to expand the proteome diversity
with a prevalence of up to 60% of all human genes (Stamm
et al. 2005). Several genes encode transcripts that are alter-
natively spliced to produce up to tens of thousands of dif-
ferent mRNAs (Graveley 2001). The CD44 gene is becoming
a model for the study of loci that undergo complex alter-
native splicing to originate a wide diversity of proteins. The
category of complex alternative splicing has been applied to
genes that have multiple variable exons that appear to be
included in or excluded from the processedmRNA in a com-
plex manner to produce multiple mRNA isoforms from the
same gene (Breitbart et al. 1987).
The CD44 family of cell-surface glycoproteins mediates
the response of cells to their cellular microenvironment
by regulating growth, survival, differentiation, and motility.
All CD44 proteins are encoded by a single and highly
conserved gene containing 20 exons, 12 of which undergo
alternative splicing. CD44 exons are distributed in the gene
in four regions: two constant regions consisting of exons
1–5 and exons 15–17, which are subject to general constitu-
tive splicing; a region composed of exons 18 and 19, which
show an alternate use of a short or long cytoplasmic tail,
respectively; and a central region that spans exons 6a–14,
also known as variable exons v1–v10. Complex alternative
splicing applies to this central region, which is responsible
for the incorporation of the variable domains to shape,
predominantly, the extracellular, membrane-proximal stem
structure of the protein (Stamenkovic et al. 1989; Screaton
et al. 1992; Bajorath 2000; Ponta et al. 2003).
The expression of certain CD44 isoforms has been
implicated in important physiological and pathological
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conditions, including cell adhesion and migration, hema-
topoiesis, lymphocyte activation, assembly of extracellular
matrix, and metastatic spread of tumors (Herrlich et al.
1993; Gunthert et al. 1995; Ruiz et al. 1995; Lesley et al.
1997). We have previously used human breast ductal
carcinoma to show that the CD44 isoform expression pat-
tern of the breast carcinoma and its lymph-node metastases
is equivalent, presenting a stepwise inclusion of variable
exons (Roca et al. 1998). Variable exon inclusion in this
model starts with the 39-most variable exons (i.e., v10 and
v9) in low molecular weight isoforms and gradually moves
toward 59 variable exons (i.e., v2) with a subsequent in-
crease in isoform molecular weight. In contrast, normal
cells express low molecular weight CD44 isoforms. This
alternative splicing pathway, that reflects a 39-to-59 direc-
tional and stepwise inclusion of variable exons, is distin-
guishable from an alternative splicing pathway that involves
exclusively variable exon v3, observable in both normal and
carcinoma breast tissue. Exon v3 is subject to the 39-to-59
exon inclusion preference but is also present in a low
molecular weight isoform corresponding to CD44 v3 alone.
These pathways are not mutually exclusive and can be easily
integrated into a single hypothetical model of CD44 com-
plex alternative splicing (Roca et al. 1998).
Here we report the role of CD44 v3 exon sequences in
v3 splicing using deletion mutants and extensive site-directed
mutagenesis. We found a cis-acting splicing enhancer of
novel structure and organization within exon v3, and we
provide proof of function and mode of operation both in
the context of CD44 and when located in an exogenous
gene. The significance of these findings is discussed in light
of the operational nature of multisite and bidirectional
splicing enhancers described for other gene loci.
RESULTS
Alternative splicing of CD44 v3 is independent from
flanking intron length or sequence
Previous reports have described the capacity of CD44 exon
v3 to be included in or excluded from the final CD44
mRNA in a manner specific for v3 and independent from
the general 39-to-59 directional variable exon inclusion
trend (Roca et al. 1998; Zhu et al. 2003). In order to map
the splicing regulatory elements within v3, we performed a
complete dissection of this exon by exon trap and muta-
genesis experiments (Fig. 1A).
Human CD44 v3 exon spans 126 base pairs (bp) and is
flanked by introns 6 and 7, which are 1246 and 2835 bp in
length, respectively. Experimental constrains prompted the
use of a shortened version of such introns in exon trap
experiments concerning v3 (Fig. 1B). The influence of
intron length on splicing efficiency has been studied and
reported to be inversely correlated to exon inclusion in some
instances during CD44 splicing (Bell et al. 1998). Confir-
mation that intron length does not affect v3 inclusion was
provided by means of transient transfection of a shortened
version of both flanking introns whenever the authentic
splice sites are left intact (Fig. 1B, lane 3). When the 59 splice
site (59ss) was mutated from GTAAG to GTAgG, v3 was
excluded from the final mRNA (Fig. 1B, lane 4). Full
inclusion of exon v3 in the shorter intron construct implies
that introns 6 and 7 contain no elements necessary for v3
splicing and that alternative splicing control must therefore
reside within exon v3 itself (Fig. 1B, cf. lanes 2 and 3).
CD44 v3 inclusion is regulated by an internal
splicing enhancer
In an attempt to locate the elements regulating the
alternative splicing of v3, four regions (A, B, C, and D)
spanning the whole of v3 were arbitrarily defined and
deleted independently to construct exon trap deletion
mutants Del A (nucleotides 4–25), Del B (nucleotides
21–61), Del C (nucleotides 57–93), and Del D (nucleotides
94–121) as shown in Figure 2A. Subsequent transient
transfection of these constructs into the MCF-7 cell line
and RT-PCR analysis of the spliced products (Fig. 2B)
revealed a 30% drop in inclusion efficiency for the Del B
construct (Fig. 2B, lane 3) and a minor decrease in
inclusion in the case of Del D (Fig. 2B, lane 5). These
findings indicate the presence of exonic splicing enhancers
in these regions. Inclusion of the previously described
(49) pseudo-exon appeared in the Del B construct. This
pseudo-exon is generated from a cryptic 39 splice site (39ss)
in intron 6, 49 nucleotides (nt) upstream from the classical
39ss of exon v3 (Vela et al. 2006) as seen in Figure 1A.
Region B was further divided into four subregions,
namely, B1 (nucleotides 22–33), B2 (nucleotides 32–42),
B3 (nucleotides 41–51), and B4 (nucleotides 50–61), and
four independent deletion mutants spanning each of these
subregions were constructed (Fig. 2C). Exon trap analysis
of these constructs (Fig. 2D) did not show the expected
decrease in v3 inclusion when compared to the original wt
v3 construct. A detailed analysis of the sequences deleted in
small deletion mutants revealed that a 9-bp sequence motif
(AAATGAAGA), named X, was present in all four con-
structs, and that whenever this sequence was interrupted
during the generation of the deletion, the motif was
reconstructed after rejoining the sequences downstream
(see Fig. 2C). In order to test the hypothesis that this 9-nt
motif could indeed be responsible for alternative splicing
control of v3, the sequence was inserted into the Del B
construct (Fig. 3A) and analyzed by transient transfection
into MCF-7 and RT-PCR (Fig. 3B). Insertion of the 9-nt
oligo into Del B (Fig. 3B, construct Del B Ins Xs) restored
the phenotype to wt v3 inclusion levels (Fig. 3B, lane 2),
while insertion of the antisense version of this sequence
into the same site (Fig. 3B, construct Del B Ins Xas) did not
change v3 inclusion levels (Fig. 3B, cf. lanes 1 and 3). This
CD44 v3 splicing enhancer
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finding reveals that the X nonamer motif is playing a role
in v3 inclusion in these constructs.
Positive exonic cis-acting elements, known as exonic
splicing enhancers (ESEs) are often found in a purine-rich
context and may be functionally associated to the latter
(Cartegni et al. 2002). The v3 sequence contains seven GAR
motifs which may contribute during splicing regulation as
reported in other exons (Lavigueur et al. 1993; Watakabe
et al. 1993; Xu et al. 1993; Bourgeois et al. 1999). In order
to test their level of contribution in the context of the X
nonamer described above, the Del B3 construct was sel-
ected for transfection experiments as it contains only one X
nonamer with a single internal and three flanking GAR
motifs. These GAR motifs have been mutated from GAA to
cAA and from GAG to cAG (Fig. 4A) and tested by tran-
sient transfection. These experiments (Fig. 4B) show that
flanking GAR motifs have no effect on splicing (Fig. 4B,
lanes 2–5), and mutation of the internal motif carries a
marginal drop in exon inclusion (Fig. 4B, lanes 6 and 7),
suggesting that v3 inclusion requires additional cis-acting
elements, contrary to the situation reported for other ESEs
(Tanaka et al. 1994; Ramchatesingh et al. 1995).
CD44 v3 splicing enhancer motifs are functional
in a different gene context
Region B contains two copies of the X motif as a tandem
repeat, and a 7-nt version of this motif (ATGAAGA),
named Y, is present as a single copy in the D region (Fig.
2A) that also affects, albeit to a lesser extent, the inclusion
of v3 (Fig. 2B, lane 5). Functional proof of the inherent
splicing enhancing capacity of the X nonamer and Y
heptamer was obtained by their independent insertion in
the context of an heterologous exon in the BRCA1 mini-
gene system. The BRCA1 minigenes consist of exons 17, 18,
and 19 of the human BRCA1 gene, where the introns
flanking exon 18 have been shortened (Liu et al. 2001).
In the wild-type version (BRCA1 wt), exon 18 is efficiently
included. However, a G/T transversion at position 6 of
exon 18 disrupts a critical ESE, leading to exon 18 skipping
FIGURE 1. CD44. (A, top) Genomic structure of the human CD44 gene (gray boxes, constitutive exons; white boxes, alternative exons; black box,
variable exon v3; black line, introns). (Middle) Partial structure of v3 minigene. The reporter v3 minigene containing a contiguous genomic
fragment of CD44 v3 and flanking introns was cloned in the polylinker of the exon trap vector (pET). Promoter (RSV LTR), insuline (Ins 1 and
Ins 2) exons, CD44 intron 6 containing the 49-bp pseudo-exon (gray line), v3 (black box), intron 7, and possible splicing routes (thin lines) are
indicated. (Bottom) CD44 exon v3 sequence: upper case, exon; lower case, intron boundaries; lower-case italics, 49-bp pseudo-exon. (B, top)
Intron length in v3 minigenes. v3 minigene contains full-length introns 6 and 7. In the v3 short minigene, intron 6 was shortened from 1246 to
233 bp and intron 7 from 2835 to 160 bp. (Bottom) Transient transfection of the minigenes in the MCF-7 cell line: lane 1, vector without insert;
lane 2, v3 with full-length flanking introns 6 and 7; lane 3, v3 with shorter versions of introns 6 and 7; lane 4, v3 with full-length introns containing
a point mutation in the 59splice site (GTAAG to GTAgG).
Vela et al.
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(BRCA1 NL). Both the X nonamer and the Y heptamer
were independently recreated in the BRCA1 NL minigene
near the 39 end of exon 18, where the sequence AAATG
GGTA was mutagenized to AAATGaagA (BRCA1 NL X)
and to tgATGaagA (BRCA1 NL Y) (Fig. 5A). RT-PCR
analysis (Fig. 5B) showed that both elements rescue exon 18
inclusion (lanes 3 and 4), and demonstrated that both the X
nonamer and the Y heptamer are bona fide ESEs that could
function in an exonic context different from the CD44
gene. From that moment the AAATGGGTA sequence
was named X mutant (Xm) and ATGGGTA sequence was
named Y mutant (Ym), and they were used as negative-
splicing control ESEs in subsequent experiments.
CD44 v3 splicing enhancer operates as multisite
and bidirectional element
If an ESE is important for exon v3 inclusion, then the X
nonamer and Y heptamer sequences within v3 should be
required for maximal activity. In order
to ascertain the level of cooperativity
between the tandem repeat of X and Y,
each of the three motifs within v3 was
mutated in the context of the v3 mini-
gene. The X nonamer was mutated
from AAATGAAGA to AAATGggtA
and the Y heptamer from ATGAAGA
to ATGggtA to generate Xm and Ym
(Fig. 6A) as suggested by their lack
of splicing activity in the BRCA1 NL
minigene experiments. These mutants
were transfected into MCF-7 cells
and exon inclusion analysis (Fig. 6B)
showed that mutation of one of the
three motifs present lowered exon
inclusion levels to the same extent
(Fig. 6B, lanes 2–4). Subsequent muta-
tion of any two of the motifs caused
exon skipping (Fig. 6B, lanes 5–7), as
did the triple mutant (Fig. 6B, lane 8).
These results suggest that the splicing
enhancing strength is comparable in all
three motifs, and a minimum of two
of them is required to enable splicing,
which indicates some degree of coop-
erativity between these sites.
To determine the level of coopera-
tivity and dependence on relative posi-
tioning of the X and Y motifs, a series
of mutants containing a combination
of only two motifs from X, Y, Xm, and
Ym was used in exon inclusion analysis.
These constructs were based on the Del
B3 minigene and included XX, YY, YX,
XmX, XmY, XYm, Yym, and XmYm
(Fig. 6C). These results (Fig. 6D) demonstrate that at least
two motifs are needed to maintain exon inclusion during
splicing (Fig. 6D, lanes 1–4), and mutation of one of them,
independently of position, leads to a dramatic increase in
exon skipping (Fig. 6D, lanes 5–8). Mutation of both sites
eliminates detectable v3 inclusion (Fig. 6D, lane 9). Fur-
thermore, this result suggests that whenever there is only
one functional motif, X and Y have slightly different prop-
erties, as X retains some function in both positions and Y
only exerts some promotion on splicing in its original
position relative to X (Fig. 6D, cf. lanes 5 and 8). This
position-dependent effect is commonplace during splicing
regulation (Goren et al. 2006). In addition, cooperativity
between motifs is gene context-dependent as either motif
by itself promotes efficient splicing in the BRCA1 experi-
ments (Fig. 5B) but not in the CD44 v3 context. The
differences on splicing efficiency may be explained by the
synergy of any single motif with other motifs already
present in the BRCA1 exon 18 or to exon context effects,
FIGURE 2. Deletion mutants. (A) Large deletion mutants. CD44 exon v3was arbitrarily divided
into four regions: A, nucleotides 4–25; B, nucleotides 21–61; C, nucleotides 57–93; D, nucleotides
94–121. Deletions of each region were created in the context of pET v3with short introns by PCR
and subcloning procedures. Locations of v3 splicing enhancer motifs (X and Y) are indicated. (B)
RT-PCR amplification of splicing products after transient transfection of large deletion mutants
in the MCF-7 cell line: lane 1, v3; lane 2, Del A; lane 3, Del B; lane 4, Del C; lane 5, Del D. Extra
band (*) corresponds to (49) pseudo-exon previously described (Vela et al. 2006). (C) Small
deletion mutants. CD44 v3 B region was subdivided into four regions: B1, nucleotides 22–33; B2,
nucleotides 32–42; B3, nucleotides 41–51; B4, nucleotides 50–60. Deletions of each region were
created in the v3 construct by PCR and subcloning. In bold, repeated X element is indicated. (D)
RT-PCR amplification of splicing products after transient transfection of small deletion mutants
in the MCF-7 cell line: lane 1, Del B1; lane 2, Del B2; lane 3, Del B3; lane 4, Del B4.
CD44 v3 splicing enhancer
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such as differences in relative position of the motif within
the exon, exon size, or identity of the splice sites. It is not
possible, on the basis of the data provided herein, to ascribe
the cause of such differences to one, several, or all of the
effects listed above.
The first step in the splicing of an exon involves the
recognition of both 59ss and 39ss (Reed and Palandjian
1997). Although the recognition of one splice site often
facilitates the use of the other through a process known as
exon definition, the two splice sites can also be recognized
independently and are both potential sites of regulation
(Reed 1996; Graveley 2000). To investigate further which
of the splice sites of exon v3 was regulated by the X and
Y motifs, single-intron minigene constructs were made
in which exon v3 was truncated either immediately
upstream of the 59ss or immediately downstream of
the 39ss, yielding minigene constructs v3-i6 and v3-i7,
respectively.
In v3-i6 minigenes, the 59ss and intron 7 were deleted in
order to characterize the regulation of the 39ss by v3 ESE
(Fig. 7A). In this context, all combinations of XXY mutants
were created and splicing efficiency of intron 6, via v3 39ss,
was analyzed by RT-PCR (Fig. 7B). In these constructs, two
cryptic 39ss are functional: the previously described (49)
39ss (Vela et al. 2006) and the (+27) 39ss. Analysis of
splicing efficiency considered the use of the authentic v3
39ss versus the cryptic 39ss. Mutation of one of the motifs
maintained splicing in all constructs (Fig. 7B, lanes 2–4),
but mutation of two motifs demonstrated that splicing via
FIGURE 3. Insertion mutants. (A) Functional proof in CD44 con-
structs was approached by insertion of double-stranded oligonucleo-
tides into the Del B mutant and RT-PCR tests of their splicing
capacity. Del B Ins Xs mutant was generated by insertion of the
AAATGAAGA oligonucleotide. Del B Ins Xas mutant was generated
by insertion of the TCTTCATTT oligonucleotide. (B) RT-PCR
amplification of splicing products after transient transfection of
insertion mutants in the MCF-7 cell line: lane 1, Del B; lane 2, Del
B Ins Xs; lane 3, Del B Ins Xas. Extra bands (*) in lanes 1 and 3
correspond to the (49) pseudo-exon (Vela et al. 2006).
FIGURE 4. GAR mutants. (A) GAR motifs located in the context of
X nonamer were mutated by PCR-directed mutagenesis from the Del
B3 construct. These motifs have been mutated from GAA to cAA and
from GAG to cAG. Active GAR motifs are indicated in bold. Mutated
positions are indicated in lower case letters. Sequence corresponding
to X nonamer is indicated. (B) RT-PCR amplification of splicing
products after transient transfection of GAR mutants in the MCF-7
cell line: lane 1, Del B3 construct; lane 2, mutant 1; lane 3, mutant 6;
lane 4, mutant 2; lane 5, mutant 3; lane 6, mutant 4; lane 7, mutant 5.
Extra band (*) corresponds to the (49) pseudo-exon (Vela et al.
2006).
Vela et al.
2316 RNA, Vol. 13, No. 12
 Cold Spring Harbor Laboratory Press on August 30, 2011 - Published by rnajournal.cshlp.orgDownloaded from 
39ss was only maintained in XmXYm-i6 and XXmYm-i6
(Fig. 7B, lanes 6 and 7) and dropped to 30% in XmXmY-i6
and triple mutant constructs (Fig. 7B, lanes 5 and 8). These
results demonstrate that only the X motifs maintained
splicing via the 39ss and the Y motif failed in the rec-
ognition of the 39ss, so that intron 6 is inefficiently spliced.
In v3-i7 minigenes, the 39ss and intron 6 were deleted in
order to analyze the regulation of the 59ss by v3 ESEs (Fig.
7C). All combinations of XXY mutants were generated and
splicing efficiency of intron 7, via v3 59ss, was analyzed by
RT-PCR (Fig. 7D). In these constructs a cryptic 59ss was
also functional: (72) 59ss. Analysis of splicing efficiency
considered the use of the authentic v3 59ss versus the
cryptic 59ss. In constructs with two active motifs, splicing
via 59ss was maintained in XmXY-i7 and XXYm-i7 (Fig.
7D, lanes 2 and 4) and was reduced to 60% in XXmY-i7
(Fig. 7D, lane 3). Mutation of two motifs caused a drop to
40% of splicing efficiency via 59 ss in XmXmY-i7 and
XmXYm-i7 (Fig. 7D, lanes 5 and 6) and complete exon
exclusion in XXmYm-i7 and triple-mutant constructs (Fig.
7D, lanes 7 and 8). These results demonstrate that the
second X and Y motifs maintained splicing via 59ss, but the
first X does not participate in the splice-site recognition
and thus intron 7 cannot be spliced.
Taken together, the combined results from the one-
intron experiments suggest that there is a cooperative
action between the motifs for the recognition of the splice
sites. This cooperativity contributes to the splicing activity
when two active motifs are present in the construct.
However, when only one motif remains active, it manifests
directional action in splice-site recognition. In this way, the
first X nonamer acts on the recognition of the 39ss, the
second X nonamer acts in the recognition of both splice
sites (bidirectional action), and the Y heptamer acts on the
recognition of the 59ss.
Background splicing via 39ss in v3-i6 minigenes suggests
that other factor(s) are influencing 39ss usage, in this
construct specifically, as compared with v3-i7 experiments,
or other results presented herein where no splicing is
achieved in the absence of ESE. Likewise, v3-i6 splicing
analyses do not reach expected 100% efficiency as noted in
the rest of our results. This may respond to the presence of
the active cryptic (49) 39ss, which competes in this test.
Functional demonstration of the use of this cryptic splice
site under physiological conditions is available elsewhere
(Vela et al. 2006).
The consensus sequence of mammalian 59ss is CAG/
GUAAGU (Sheth et al. 2006). The 59ss of CD44 exon v3
differs from the consensus at positions 1, 2, and +6.
The consensus sequence of mammalian 39ss is UUUUUU
CCCUNCAG/G. The 39ss of CD44 exon v3 differs from the
consensus at positions 5, 8, 9, and 10. To test the
influence of 59ss and 39ss strength on v3 splicing, we
constructed minigenes in which the splice sites of v3 were
mutated to match the consensus sequence of mammalian
splice sites (Fig. 8A). These constructs, with active enhancer
(XXY) or triple mutant enhancer (XmXmYm), were tran-
siently transfected in MCF-7 and analyzed by RT-PCR
(Fig. 8B). While the splicing enhancer was active, consensus
splice sites did not increase the splicing efficiency, which
was already maximal (Fig. 8B, lanes 2–4). In the case of
mutant ESE, the consensus splice sites marginally increased
v3 inclusion, and only when both splice sites were im-
proved to match the consensus did exon inclusion reach
significant levels (Fig. 8B, lanes 6–8). These observations
indicate that changing the v3 splice sites to perfectly match
the consensus is not sufficient for constitutive inclusion of
v3 and that the presence of the ESE described herein is
required to achieve efficient exon inclusion.
All minigene constructs described in this work were also
tested in the monkey kidney COS-7 cell line, with equiv-
alent results (data not shown). This implies that CD44 exon
v3 regulation by the XXY ESE is not restricted to human
cells but that it is also operational in other animal models
and tissue types.
FIGURE 5. Proof-of-function constructs. (A) Functional proof in the
heterologous context of BRCA1 minigene system. X and Y motifs were
created in BRCA1 NL minigenes by PCR-directed mutagenesis. (B)
RT-PCR amplification of splicing products after transient transfection
of BRCA1 minigenes into the MCF-7 cell line: lane 1, BRCA1 wt; lane
2, BRCA1 NL; lane 3, BRCA1 NL X; lane 4, BRCA1 NL Y.
CD44 v3 splicing enhancer
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DISCUSSION
We had previously described that splicing of human CD44
exon v3 is regulated independently from other variable
exons in a breast tissue model. Here we exhaustively dis-
sected the sequence elements that dictate the splicing behav-
ior of exon v3, by minigene transfection and RT-PCR
analysis. This strategy has allowed us to define exon se-
quences whose mutation decreases the abundance of spliced
transcripts containing exon v3, in particular a tandem
nonamer (AAATGAAGA, named the X motif) and an
heptamer (ATGAAGA, named the Y motif). These motifs
act cooperatively as their presence together within v3
regulates exon inclusion. Their action is differential with
respect to the splice-site target abutting v3. The first X
motif acts on the 39ss, the second X motif acts on both
splice sites (as a bidirectional ESE), and the Y motif acts on
the 59ss. Both of these sequence motifs retain their splicing
enhancing activity in a heterologous gene context in tran-
sient transfection experiments, defining them as bona fide
ESEs. We also show that the multisite v3 splicing enhancer
is functional, irrespective of flanking intron length and its
spatial organization within v3. As CD44 v3-cassette inclu-
sion is detected in both normal breast tissue and in breast
FIGURE 6. Point mutants. (A) XX and Y point mutants were generated by PCR-directed mutagenesis from the v3 minigene. Active X and Y
motifs are indicated in bold. Mutated positions are indicated in lower case. (B) RT-PCR amplification of splicing products after transient
transfection of XX and Y point mutants in the MCF-7 cell line: lane 1, XXY; lane 2, XmXY; lane 3, XXmY; lane 4, XXYm; lane 5, XXmYm; lane 6,
XmXYm; lane 7, XmXmY; lane 8, XmXmYm. (C) X and Y point mutants were generated by PCR-directed mutagenesis from the Del B3 construct.
Active X and Y motifs are indicated in bold. Mutated positions are indicated in lower case. (D) RT-PCR amplification of splicing products after
transient transfection of X and Y point mutants in the MCF-7 cell line: lane 1, XY; lane 2, XX; lane 3, YY; lane 4, YX; lane 5, XmX; lane 6, XmY;
lane 7, XYm; lane 8, YYm; lane 9, XmYm. Extra bands (*) correspond to the (49) pseudo-exon (Vela et al. 2006).
Vela et al.
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carcinoma (Roca et al. 1998), its regulation through the
ESE described herein may be biologically relevant in both
normal and transformed cells.
Expression of minigene pre-mRNAs by transient trans-
fection provides a rapid assay for loss-of-function/gain-of-
function analyses and for cis- and trans-acting factors that
affect splicing regulation (Cooper 2005). A different and
complementary approach to identify ESEs in vitro involves
biocomputing methods based on the over-representation of
these sequences in exons. We have evaluated the level of
theoretical confidence for the elements functionally iden-
tified in exon v3 using available biocomputing resources.
Fairbrother’s relative enhancer and silencer classification by
unanimous enrichment (RESCUE) biocomputing method
identified 238 hexamer sequences that occurred more fre-
quently in exons with weak splice sites (Fairbrother et al.
2002). Submission of wild-type CD44 v3 sequences to this
Web server (Fairbrother et al. 2004) predicted three ESE
FIGURE 7. Single-intron minigenes. (A) v3-i6 minigenes were generated by PCR subcloning from v3 constructs, deleting the v3 59ss and intron
7. Exon sequences are indicated in upper case. Intron sequences are indicated in lower case. 39ss are indicated in bold. Positions of cryptic 39ss are
numbered according to authentic 39ss. (B) RT-PCR amplification of splicing products after transient transfection of v3-i6 constructs in the MCF-
7 cell line. XX and Y mutants were generated by PCR-directed mutagenesis. RT-PCR products generated by the use of the different 39ss were
quantified as net intensity of each band. Splicing efficiency of intron 6 via v3 39ss, was defined as (use of authentic v3 39ss)/[use of authentic v3
39ss + (49) 39ss + (+27) 39ss]: lane 1, XXY-i6; lane 2, XmXY-i6; lane 3, XXmY-i6; lane 4, XXYm-i6; lane 5, XmXmY-i6; lane 6, XmXYm-i6; lane
7, XXmYm-i6; lane 8, XmXmYm-i6. (C) v3-i7 minigenes were generated by PCR subcloning from v3 constructs, deleting intron 6 and the v3 39ss.
Exon sequences are indicated in upper case. Intron sequences are indicated in lower case. 59ss are indicated in bold. Position of the cryptic 59ss is
numbered according to authentic 59ss. (D) RT-PCR amplification of splicing products after transient transfection of v3-i7 constructs in the MCF-
7 cell line. XX and Y mutants were generated by PCR-directed mutagenesis. RT-PCR products generated by the use of different 59ss were
quantified as net intensity of each band. Splicing efficiency of intron 7 via 59ss, was defined as (use of authentic v3 59ss)/[use of authentic v3 59ss +
(72) 59ss]: lane 1, XXY-i7; lane 2, XmXY-i7; lane 3, XXmY-i7; lane 4, XXYm-i7; lane 5, XmXmY-i7; lane 6, XmXYm-i7; lane 7, XXmYm-i7; lane
8, XmXmYm-i7.
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hexamer matches in the X motif (AATGAA, ATGAAG
and TGAAGA) and two ESE hexamers in the Y motif
(ATGAAG and TGAAGA). Consistent with this prediction,
submission of mutated v3 sequences (XmXmYm) pro-
vided no matches for hexamer enhancers. RNA octamers
described by Zhang and Chasin (2004) are found more
frequently in exons than in pseudo-exons or intronless
genes. Octamers with a higher prevalence in exons are
designated as putative exonic splicing enhancers (PESEs),
and those with lower prevalence in exons are designated as
putative exonic splicing silencers (PESSs). Analysis of CD44
exon v3 sequences using this algorithm (Zhang et al. 2005)
reveals several overlapping PESEs in wild-type v3 sequences—
five in the XX region (ATGAAGAA, TGAAGAAA, GAA
GAAAA, ATGAAGAT, and GAAGATGA) and two in the
Y motif (GATGAAGA and ATGAAGAT)—but no PESSs.
Interestingly, when mutated v3 sequences are tested
(XmXmYm), the PESEs theoretically identified in wild-
type v3 become PESSs. This observation supports the pres-
ence of the two motifs which we have functionally charac-
terized as parts of a multisite ESE for v3 in this report.
Furthermore, the motifs described during this work are
represented in the collection of 285 exonic splicing regu-
latory sequences (ESRs) recently reported by the Ast group
(Goren et al. 2006). The XX tandem nonamer contains
several hexamers predicted by Goren et al. (2006) as ESR:
AATGAA, GAAGAA, AAGAAA, and GAAAAT. In addi-
tion, the Y heptamer overlaps with the GATGAA and GAA
GAT hexamers. Some of the hexamers contained in that
collection have been validated in vivo to show enhancer
or silencer capacity depending on the ESR environment
(Goren et al. 2006). Our assays of the effect on splicing of
the XX and Y motifs have shown only enhancing capacity.
However, whether they can also function as silencers in
other positions, in the same context or in different gene
contexts, has not been demonstrated.
The homologs of human CD44 exon v3 in other
organisms maintain a high degree of evolutionary conser-
vation. The enhancer motifs X and Y described herein are
conserved in other primates like Macaca mulatta (GenBank
NC_007871) and Pan troglodytes (GenBank NC_006478).
In other mammals like Mus musculus (GenBank NT_
039207), Rattus norvegicus (GenBank NM_012924), and
Canis familiaris (GenBank L28931), the first X motif differs
in one unique nucleotide position and the second X motif
and Y motif remain 100% conserved. Based on its behavior
in MCF-7 and COS-7 cell lines, where two of the motifs are
enough to address v3 inclusion, we would expect v3 in these
organisms to promote its inclusion via the same ESE.
The presence of two contiguous identical nonamers (XX)
in CD44 exon v3 resembles other known multisite ESEs.
The doublesex repeat element (dsxRE) from Drosophila
contains six nearly identical copies of a 13-nt repeat
sequence, each of which is recognized by regulatory pro-
teins. Each repeat constitutes an independent and equiva-
lent binding site for Tra and Tra2, and cooperative binding
occurs within but not between individual repeats (Hertel
and Maniatis 1998). Multiple repeats of the dsxRE increase
splicing efficiency by increasing the probability of splice-
site activation rather than by formation of multiple
FIGURE 8. Characterization of elements involved in CD44 exon v3
splicing. (A) Localization of v3 splicing elements. Active XX and Y
motifs are indicated as small white boxes. Mutant XX and Y motifs are
indicated as small gray boxes. v3 splice-site sequences are indicated.
Upper case: exonic nucleotides. Lower case: intronic nucleotides. v3
splice sites were mutated to match consensus sequences (39ss and/or
59ss up) by PCR-directed mutagenesis from v3 and v3m constructs.
Mutated positions are indicated in bold. (B) RT-PCR amplification of
splicing products after transient transfection of splice-site mutants in
the MCF-7 cell line: lane 1, v3; lane 2, v3 39ss up; lane 3, v3 59ss up;
lane 4, v3 3959ss up; lane 5, v3m; lane 6, v3m 39ss up; lane 7, v3m 59ss
up; lane 8, v3m 3959ss up. Extra bands (*) correspond to the (49)
pseudo-exon (Vela et al. 2006).
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interactions between the enhancer complex and compo-
nents bound to the weak 39ss of the dsx pre-mRNA.
Likewise, the fruitless repeat element (fruRE) from Dro-
sophila consists of three 13-nt repeat elements. In this case,
only one repeat element within fruRE is necessary and
sufficient to activate the female-specific splice site (Lam
et al. 2003). fruRE and dsxRE function similarly in activat-
ing 59ss and 39ss, respectively, and these ESE complexes are
capable of recruiting targets that contain multiple spliceo-
somal components required for the initial recognition of
59ss and 39ss. The precise mechanistic nature of the CD44
exon v3 ESE awaits further characterization, but an
approximation to its mode of operation is provided by
its preference in targeting specific splice sites.
Most ESEs have been shown to promote recognition of
either the upstream 39ss or the downstream 59ss. Only a
few ESEs have been shown to simultaneously promote the
recognition of both upstream and downstream splice sites,
thus working as a bidirectional splicing enhancer. Bourgeois
et al. provided the first characterization of a purine-rich
bidirectional splicing enhancer (Pu1 and Pu2), in the
adenovirus E1A pre-mRNA (Bourgeois et al. 1999). Pu1
is involved in splicing activation through the 59ss, whereas
both Pu1 and Pu2 are required for an optimal activation of
the 39ss. In addition to the high level of sequence identity
between Pu2 and the v3 X motif, this model may set a pre-
cedent for the v3 ESE function, where the first X is involved
in 39ss recognition and the second in both 59ss and 39ss
activation.
In order to identify putative ESEs responsive to human
SR proteins SF2/ASF, SC35, SRp40, and SRp55, CD44 v3
sequences were analyzed with the ESEfinder web server
(Cartegni et al. 2003). This approach failed to match SR-
responsive elements in the XX and Y regions, suggesting
that the effect of these motifs is not mediated by any of
these four proteins. Submission of CD44 v3 sequences to
ESRsearch web tool (Goren et al. 2006) had equivalent
results: none of the motifs contained in v3 ESE matched
any known trans-factors’ binding site. Our attempts to
identify specific trans-factors acting on the isolated motifs
of the v3 ESE, by RNA-affinity precipitation, have system-
atically failed to reveal specific RNA–protein binding (data
not shown). This failure calls for a change in the trans-
factor identification strategy that should consider the novel
v3 composite ESE as a whole functional splicing enhancer
unit, in line with our functional cis-acting characterization
that defines a complex operational multisite unit during the
splicing process.
The sequence and functional information generated in
the course of this work sets the basis for trans-factor iden-
tification and contributes to the construction of a full
mechanistic model for CD44 alternative splicing. We re-
port a novel structure and organization within exon v3
in the form of a functional multisite bipartite bidirectional
ESE.
MATERIALS AND METHODS
Cell culture and transfections
In order to analyze the regulation of CD44 v3 splicing in a breast
tissue model, the MCF-7 cell line was selected as an in vitro model
of human breast carcinoma cells due to its high efficiency of trans-
fection, in our experience, during transient transfection assays as
compared to other cell lines. The COS-7 cell line (African green
monkey kidney) was selected as a model unrelated to human
breast tissue.
Cell lines were purchased from the American Type Culture
Collection (ATCC). MCF-7 cells were cultured in Minimum
Essential Medium-Eagle supplemented with 10% fetal calf serum,
2 mM L-glutamine, 0.1 mM nonessential amino acids, 1 mM
sodium pyruvate, 0.01 mg/mL bovine insuline, 100 units/mL
penicillin and gentamicin. COS-7 cells were grown in Dulbecco’s
modified Eagle medium supplemented with 10% fetal calf serum,
2 mM L-glutamine, 100 units/mL penicillin and gentamicin. Cell
lines were tested periodically for the absence of mycoplasma
contamination following a standard PCR method. MCF-7 and
COS-7 cells were transiently transfected using 200 ng of DNA and
the LipofectAMINE PLUS Reagent (Gibco) according to the
manufacturer’s instructions. Cells were harvested 24 h after
transfection to extract total RNA.
CD44 v3 minigene constructs
A fragment of the human genomic CD44 sequence (GeneBank
NT_009237), containing exon v3 and flanking introns 6 and 7,
was amplified by PCR using two sets of primers containing XbaI
restriction sites, I6FX (59-GCGTATGTTTTCTAGACAGCCTT
GAATAAT-39) with I7R5bX (59-AATGAATCATCATAGACCAG
GTTGT-39) and I6F3X (59-CTTTCAGCTTTCTAGAAGAGAATA
TTCAGTT-39) with I7R1X (59-ATATTTTCCCCAACTTCTAGA
AACATTCTA-39). The first set, I6FX and I7R5bX, amplifies the
full length of introns 6 and 7. The second set, I6F3X and I7R1X,
amplifies from nucleotide 1012 in intron 6 to nucleotide 160 in
intron 7.
The genomic inserts were cloned into a pUC18 vector with
SureClone Ligation Kit (Pharmacia) and subcloned into the XbaI
site within the multiple cloning site of the mammalian expression
exon trap (pET) vector (MoBiTec), resulting in the minigene con-
structs pET v3 and pET v3 short.
Large deletion mutants were generated by combining PCR
fragments from the above constructs, giving rise to deletions in
the v3 exon sequence. Del A mutant was generated with primers
F59-v3Acc (59-CCATGGTACCAGGCTGGGAGCCAAATGAA-39)
and R59-v3Acc (59-AAGAGGTACCTGTTGTTGTGACTTGCAT
TA-39), deleting from nucleotide 4 to nucleotide 25. Del B mutant
was generated with primers F59v3Xho (59-AGATGCTCGAGACA
GACACCGCAGTTTTTC-39) and R59v3Xho (59-GCCTCTCGA
GATGGTATTTGAAGACGTAC-39), deleting from nucleotide 21
to nucleotide 61. Del C mutant was generated with primers
F39v3Nsi (59-GATCATGCATTGATGATGATGAAGATTTT-39)
and R39v3Nsi (59-GTCTCATAGCATCTTCATTTTCTTCATTT
GG-39), deleting from nucleotide 57 to nucleotide 93. Del D
mutant was generated with primers F39v3Sph (59-TTATCG
CATGCACCAGTAAGAATAATCAAT-39) and R39v3Sph (59-AT
CATGCATGCCTGATCCAGAAAAACTGAG-39), deleting from
CD44 v3 splicing enhancer
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nucleotide 94 to nucleotide 121. PCR fragments were in-
serted into pUC18 vectors, sequenced, and subcloned into pET
vectors.
Small deletion mutants were generated by inserting PCR frag-
ments into the Del B construct. Del B1 mutant was generated with
primers DelB1F (59-TCGAGCCAAATGAAGAAAATGA-39) and
pETR (59-ATGGGTACCGAGCTCCAC-39). Del B2 mutant was
generated with primers DelB2F (59-TCAGCAGGCTGGGAA
GAAAATGAAGATGAAAGA-39) and pETR. Del B3 mutant was
generated with primers pETF (59-CCTCGAGGTCGACGGT
AT-39) and DelB3R (59-TCTTTCATCTTCATTTGGCTCCCAGC
CTG-39). Del B4 mutant was generated with primers pETF and
Del B4R (59-TCATTTTCTTCATTTGGCTC-39).
Insertion mutants were generated by insertion of double-
stranded oligonucleotides into the Del B mutant. Del B Ins Xs
mutant was generated by insertion of the AAATGAAGA oligonu-
cleotide. Del B Ins Xas mutant was generated by insertion of the
TCTTCATTT oligonucleotide.
Point mutants were generated by PCR with the Site Directed
Mutagenesis Kit (Stratagene) according to the manufacturer’s
instructions.
Single-intron constructs were synthesized using PCR from pET
v3 short and v3 XmXmYm constructs. For v3-i7 constructs, a PCR
primer was used that initiates v3 at an EcoRV restriction site
followed by nucleotide 10. For v3-i6 constructs, a PCR primer was
used that terminates v3 at nucleotide 111 followed by an EcoRV
restriction site.
BRCA1 minigene constructs
BRCA1 minigene NL (Liu et al. 2001) consisting of exons 17, 18,
and 19 (kindly provided by Dr. A. Krainer, Cold Spring Harbor
Laboratory) was excised from its original pIND vector and sub-
cloned into the BamHI/XbaI sites of the pET vector for exon trap
experiments.
All constructs were confirmed by sequencing with BigDye
Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems).
RT-PCR analysis
RT-PCR was performed from 2 mg of total RNA extracted with
Ultraspec RNA solution (Biotecx Laboratories). The first-strand
reaction was performed with the First-Strand Synthesis Kit
(Pharmacia), with Trap#1 primer (59-GATCCACGATGC-39) for
v3 minigene constructs and Random primer for BRCA1 minigene
constructs, followed by PCR using oligonucleotide primers
N59trap in Insuline exon 1 (59-CCTGCTCATCCTCTGGGAGC-
39) and N39Trap in Insuline exon 2 (59-AGGTCTGAAGGT
CACGGGCC-39).
PCR conditions were 94°C for 1 sec, 62°C for 5 sec, and 72°C
for 10 sec, for 40 cycles. Under these conditions, ratios between
the amplification of exon inclusion and exon skipping products
did not change when different numbers of cycles were performed.
PCR products were separated by electrophoresis in a 2.5% agarose
gel, visualized with ethidium bromide stain, and quantified as net
intensity of each band with the Kodak-EDAS 120 system. Exon
inclusion was defined as inclusion/(inclusion + skipping). Results
were confirmed in at least three independent transient trans-
fection assays. The variability between independent assay results is
expressed asstandard deviation bars in all graphics.
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